In Brief
This article was originally published in The Rose Sheet
Executive Summary
FDA issued warning letters Sept. 21 to two skin-care companies it says are making unapproved drug claims. More news in brief.
You may also be interested in...
In Brief
The “Chemical Safety Improvement Act of 2013” would reform chemicals regulation in the U.S. by requiring manufacturers to submit safety data and prioritizing high-risk substances for further evaluation by the Environmental Protection Agency. More news in brief.
FDA Warns Lancome For Gene/Stem-Cell Claims: A Signal To Marketplace?
L’Oreal/Lancome’s claims for Genifique anti-aging products, among others, identify the products as drugs under food and drug law, according to FDA’s Sept. 7 warning letter. Agency cites claims suggesting the brand’s technology “boosts the activity of genes” and “improve[s] the condition around the stem cells” – language that is not altogether unique in today’s anti-aging cosmeceutical market.
In Brief
CHPA stands up for gluten in OTCs; Sen. Durbin targets energy drink supplement labeling; CDC report delves into U.S. nutritional data; P&G files tooth whitening patent suit against Be Well Health Marketing; more news In Brief.